Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 124 WM study of ixazomib, rituximab, and dexamethasone in relapsed or progressive Waldenström's macroglobulinemia
NL-OMON55853Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jan 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, rituximab and dexamethasone in Waldenström macroglobulinemia (WM), sponsored by HOVON. Primary endpoints: Recommended phase II dose and Overall response rate. Started Jan 2015; status: recruiting.
02
Drugs
ixazomibrituximabdexamethasone
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NL-OMON55853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55853.